Long-term immunogenicity of two pediatric doses of combined hepatitis A and B or monovalent hepatitis B vaccine in 8 to 10-year-old children and the effect of A challenge dose given seven years later

Pediatric Infectious Disease Journal

Volumn 28, Issue 10, 2009, Pages 916-918

  Gilca, Vladimir ^a   Dionne, Marc ^a   Boulianne, Nicole ^a   Murphy, Donald ^b   De Serres, Gaston ^a  

^a UNIVERSITÉ LAVAL   (Canada)

^b Quebec Public Health Laboratory   (Canada)

Author keywords

2 doses; Booster; Hepatitis A and B; Long term; Vaccination

Indexed keywords

HEPATITIS A VACCINE; HEPATITIS B VACCINE; RECOMBINANT HEPATITIS B VACCINE; TWINRIX JUNIOR; UNCLASSIFIED DRUG; VIRUS VACCINE;

ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; CHILD; CLINICAL ASSESSMENT; DRUG EFFECT; FOLLOW UP; HEPATITIS A; HEPATITIS B; HUMAN; IMMUNITY; IMMUNOASSAY; IMMUNOGENICITY; NORMAL HUMAN; PEDIATRICS; PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT RESPONSE; VACCINATION;

EID: 70349681086     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3181a3ad28     Document Type: Article

References (10)

1. European Consensus Group. Are booster immunisations needed for lifelong hepatitis B immunity? Lancet. 2000;355:561-565.
2. Gilca V, Duval B, Boulianne N, et al. Impact of the Quebec school-based hepatitis B immunization program and potential benefit of the addition of an infant immunization program. Pediatr Infect Dis J. 2006;25:372-374.
3. Diaz-Mitoma F, Law B, Subramanya A, et al. Long-term antibody persistence induced by a combined hepatitis A and B vaccine in children and adolescents. Vaccine. 2008;26:1759-1763.
4. Duval B, Gilca V, Boulianne N, et al. Immunogenicity of two paediatric doses of monovalent hepatitis B or combined hepatitis A and B vaccine in 8-10 year old children. Vaccine. 2005;23:4082-4087.
5. Duval B, Gilca V, Boulianne N, et al. Comparative long term immunogenicity of two recombinant hepatitis B vaccines and the effect of a booster dose given after five years in a low endemicity country. Pediatr Infect Dis J. 2005;24: 213-218.
6. Petersen KM, Bulkow LR, McMahon BJ, et al. Duration of hepatitis B immunity in low risk children receiving hepatitis B vaccinations from birth. Pediatr Infect Dis J. 2004;23:650-655.
7. Hammitt LL, Hennessy TW, Fiore AE, et al. Hepatitis B immunity in children vaccinated with recombinant hepatitis B vaccine beginning at birth: a follow-up study at 15 years. Vaccine. 2007;25:6958-6964.
8. van der Sande MA, Mendy M, Waight P, et al. Similar long-term vaccine efficacy of two versus three doses of HBV vaccine in early life. Vaccine. 2007;25:1509-1512.
9. Hu Y, Wu Q, Xu B, et al. Influence of maternal antibody against hepatitis B surface antigen on active immune response to hepatitis B vaccine in infants. Vaccine. 2008;26:6064-6067.
10. Pham B, Duval B, De Serres G, et al. Seroprevalence of hepatitis A infection in a low endemicity country: a systematic review. BMC Infect Dis. 2005;5:56.